protein

Amino terminal fragment of human uPA

MBS135666

0.1 mg

535 USD

Protein

Amino terminal fragment of human uPA

[Amino terminal fragment of human uPA]

[urokinase-type plasminogen activator isoform 2; Urokinase-type plasminogen activator; urokinase-type plasminogen activator; U-plasminogen activator; plasminogen activator, urinary; plasminogen activator, urokinase]

[PLAU]

[PLAU; PLAU; ATF; QPD; UPA; URK; u-PA; BDPLT5; U-plasminogen activator; uPA]

UROK_HUMAN

414

>95% by SDS-PAGE analysis

Frozen liquid

4.3 mg/ml

Store at -70°C. Shelf Life: 3 years from delivery. Shipping: Ships with Dry Ice

Source: Insect cell culture

Buffer: 0.1M Tris-HCl; 0.15M NaCl; pH 7.4. Extinction Coefficient: 1.6. Volume: 0.023ml. Aliquot: 1 x 0.1 mg

Urokinase (uPA); Amino Terminal Fragment of Human uPA

The amino terminal fragment (ATF) of uPA is purified from auto-catalytic digestion of recombinant human urokinase produced in insect cells. ATF contains the Kringle and Epidermal Growth Factor domains and is separated from LMW uPA by cleavage at the Lys135-Lys136 Bond

222537759

NP_001138503.1

NM_001145031.1

P00749

18,500

ATF-2 Transcription Factor Network Pathway (138006); Blood Clotting Cascade Pathway (198840); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); DNA Damage Response (only ATM Dependent) Pathway (198827); Dissolution Of Fibrin Clot Pathway (106061); E2F Transcription Factor Network Pathway (137934); Endochondral Ossification Pathway (198812); FGF Signaling Pathway (137989)

This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2009]

uPA: Specifically cleave the zymogen plasminogen to form the active enzyme plasmin. Defects in PLAU are the cause of Quebec platelet disorder (QPD). QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins. Belongs to the peptidase S1 family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Secreted; Secreted, signal peptide; Motility/polarity/chemotaxis; EC 3.4.21.73; Protease. Chromosomal Location of Human Ortholog: 10q22.2. Cellular Component: extracellular space; cell surface; focal adhesion; extracellular region; plasma membrane. Molecular Function: protein binding; serine-type endopeptidase activity. Biological Process: regulation of cell adhesion mediated by integrin; fibrinolysis; regulation of smooth muscle cell migration; smooth muscle cell migration; response to hypoxia; regulation of receptor activity; signal transduction; proteolysis; blood coagulation; chemotaxis; regulation of cell proliferation. Disease: Quebec Platelet Disorder; Alzheimer Disease

0.1 mg

535 USD

1 mg

3655